FDA Approves Esketamine as First Monotherapy for Treatment-Resistant Depression

The US Food and Drug Administration has officially approved the nasal spray esketamine as a standalone monotherapy for treatment-resistant depression, marking a profound shift in how severe psychiatric conditions are managed. Previously, the drug—marketed by Johnson & Johnson under the brand name Spravato—was only authorized for use alongside a daily oral antidepressant. This new regulatory clearance allows patients to drop the daily pills entirely, relying solely on the rapid-acting nasal spray administered during twice-weekly clinic visits. The decision arrives after a highly anticipated Phase 3 clinical trial demonstrated that esketamine alone could drive severe depression into remission faster and more effectively than standard daily medications. For the millions of patients who have endured the grueling cycle of trial-and-error with traditional selective serotonin reuptake inhibitors (SSRIs), the approval offers a fundamentally different approach to psychiatric care.

Treatment-resistant depression (TRD) is a clinical designation applied when a patient fails to respond to at least two different antidepressant regimens. According to the National Institute of Mental Health, approximately 30 percent of individuals diagnosed with major depressive disorder fall into this category, representing a massive population living with chronic, debilitating symptoms. Traditional oral antidepressants typically take four to six weeks to build up in the system and show any therapeutic effect, a dangerous waiting period for patients experiencing acute distress or suicidal ideation. Esketamine bypasses this agonizing timeline entirely. By targeting a different neural pathway, the drug has been shown to alleviate depressive symptoms in a matter of hours, fundamentally rewriting the expectations for psychiatric intervention.

The core evidence driving the FDA's decision stems from a landmark Phase 3 randomized clinical trial published in The American Journal of Psychiatry. The study tracked over 800 patients with severe treatment-resistant depression, splitting them into cohorts receiving either esketamine monotherapy or a placebo nasal spray combined with a newly initiated oral antidepressant. The results were striking: 52 percent of the patients in the esketamine monotherapy group achieved full clinical remission at the eight-week mark, compared to just 33 percent in the control group. Furthermore, the monotherapy cohort demonstrated a significant reduction in depressive symptom scores within the first 24 hours of the initial dose. This rapid onset of action, sustained over the two-month acute phase without the chemical support of a daily pill, provided the definitive proof of concept required by regulators.[2]

To understand why esketamine succeeds where traditional drugs fail, it is necessary to look at the brain's neurotransmitter systems. Standard SSRIs, like Lexapro or Zoloft, work by increasing the availability of serotonin in the brain. Esketamine, a derivative of the anesthetic ketamine, operates on an entirely different mechanism. It acts as an NMDA receptor antagonist, triggering a massive surge of glutamate—the brain's most abundant excitatory neurotransmitter. This glutamate burst stimulates a process called synaptogenesis, rapidly prompting the brain to grow new neural connections and repair synapses that have withered under the toxic stress of chronic depression. This mechanism of action explains the drug's speed; rather than slowly adjusting chemical balances over weeks, esketamine forces an immediate structural reboot of the brain's mood-regulating networks.[3]

The ability to use esketamine as a monotherapy addresses one of the most persistent complaints in psychiatric medicine: the severe side-effect burden of daily oral antidepressants. For many patients, SSRIs and SNRIs cause significant weight gain, sexual dysfunction, insomnia, and a pervasive sense of emotional blunting. Because the previous FDA label required esketamine to be taken concurrently with an oral antidepressant, patients were forced to endure these daily side effects even if the esketamine was doing the heavy lifting in managing their mood. By dropping the daily pill requirement, the new monotherapy indication allows patients to experience the mood-lifting benefits of the glutamate surge without the chronic, systemic side effects of serotonin modulation.[1][3]

Despite the new monotherapy label, the strict logistical protocols surrounding esketamine administration remain unchanged. Because the drug can cause transient dissociation, sedation, and sharp spikes in blood pressure, it cannot be dispensed at a standard pharmacy for at-home use. Under the FDA's Risk Evaluation and Mitigation Strategy (REMS), patients must travel to a certified medical clinic to self-administer the nasal spray under the direct supervision of a healthcare provider. They are then required to remain in the clinic for a mandatory two-hour observation period until the acute psychoactive effects subside and their blood pressure stabilizes. During the initial induction phase, this means committing to two-hour clinic visits twice a week for four weeks, a significant logistical hurdle for many working adults.

When evaluating the strength of the evidence supporting this approval, the data on rapid symptom relief is overwhelmingly strong. Multiple peer-reviewed studies and years of real-world clinical data since the drug's initial adjunct approval in 2019 have consistently demonstrated its ability to halt severe depressive episodes and acute suicidal ideation within hours. The Phase 3 monotherapy trial merely confirmed that this rapid relief is intrinsic to the esketamine itself, rather than a synergistic effect of combining it with an oral antidepressant. The statistical power of the remission rates in the monotherapy cohort leaves little doubt regarding the drug's standalone efficacy during the acute phase of treatment.[2]

However, the evidence is still developing regarding the optimal long-term maintenance strategy for monotherapy patients. While the acute induction phase is well-mapped, depression is a chronic condition that often requires years of management. In the clinical trials, patients who successfully achieved remission on esketamine monotherapy were transitioned to a maintenance schedule, receiving the nasal spray once a week or once every two weeks. The open question is how long this maintenance phase must last, and whether patients who drop their daily oral antidepressants are at a higher risk of relapsing between their spaced-out clinic visits over a multi-year horizon. Long-term registry data will be required to fully understand the durability of esketamine monotherapy over a five- or ten-year period.[2][3]

The patient experience during the two-hour clinic visits is a unique aspect of this treatment paradigm. Unlike taking a pill with breakfast, receiving esketamine is an episodic, highly experiential medical event. Within minutes of administering the nasal spray, patients often experience profound dissociation—a feeling of detachment from their body or physical surroundings—along with mild visual or auditory distortions. Clinics are typically outfitted with dim lighting, reclining chairs, and noise-canceling headphones to help patients navigate this transient altered state comfortably. While these dissociative effects peak around the 40-minute mark and resolve entirely by the end of the two-hour observation window, they underscore why the FDA maintains such a tight regulatory grip on the drug's distribution.[1]

The shift to monotherapy also introduces complex new dynamics into the economics of psychiatric care. Spravato is an expensive medication, with the drug alone costing hundreds of dollars per dose, not including the facility fees and provider time required for the two-hour observation periods. When esketamine was mandated as an adjunct therapy, insurance companies often required patients to prove they were actively taking and failing a cheap generic oral antidepressant before approving the nasal spray. Now that it is approved as a frontline monotherapy for treatment-resistant cases, payers will have to adjust their coverage algorithms. While the overall cost of care may rise due to the clinic visits, health economists argue that rapidly driving patients into remission saves the healthcare system massive downstream costs associated with hospitalizations, emergency room visits, and lost economic productivity.[3]

From a broader clinical perspective, this approval accelerates a fundamental paradigm shift in how the medical establishment views psychiatric treatment. For the last forty years, the dominant model of depression care has been chronic daily dosing—taking a pill every single day to maintain a steady state of neurotransmitters. Esketamine monotherapy moves the field toward an episodic, interventional model. Patients receive a powerful, targeted treatment in a clinical setting to reset the brain's neural networks, and then live their daily lives free from the constant reminder and chemical burden of a daily psychiatric medication. This mirrors the treatment models used in oncology or rheumatology, where patients receive periodic infusions rather than daily pills.[1][3]

Furthermore, the success of esketamine monotherapy paves the way for the next generation of rapid-acting psychiatric compounds currently moving through the FDA pipeline. The regulatory and logistical frameworks established by the Spravato REMS program are actively being studied by developers of psilocybin, MDMA, and other psychedelic-assisted therapies. By proving that the healthcare system can safely accommodate and reimburse for a heavily restricted, in-clinic psychoactive treatment, esketamine has essentially built the commercial infrastructure that future rapid-acting therapies will rely upon. The monotherapy approval proves that these novel mechanisms are powerful enough to stand on their own.

Ultimately, the FDA's decision to untether esketamine from daily oral antidepressants represents a major victory for patient autonomy and evidence-based medicine. It acknowledges that for a significant subset of the population, traditional SSRIs offer more harm than help, and that forcing patients to endure those side effects to access advanced therapies is clinically unnecessary. While the logistical demands of the two-hour clinic visits remain a barrier to universal access, the ability to achieve rapid, durable remission from severe depression without the burden of a daily pill is a life-altering development for millions of patients. As clinics adapt to the new monotherapy protocols, the landscape of psychiatric care will continue its rapid evolution toward faster, more targeted, and more humane interventions.[3]